Table 2 Postoperative characteristics of included eyes.

Variable	All (n = 207)	Sutureless intrascleral IOL fixation (Yamane technique) (n = 155)	Suture transscleral IOL fixation (conventional technique) (n = 52)	P-value, univariate
Postoperative BCVA at 1 M, median [IQR], logMAR	0.05 [0–0.30]	0.10 [0–0.40]	0 [−0.08 to 0.21]	*0.01*
Postoperative anterior inflammation at 1 M, median [IQR], flare grade	14.8 [10.5–20.6] (n = 57)	14.8 [10.5–20.6] (n = 57)	N.A.
Postoperative number of corneal endothelial cells at 1 M, median [IQR]	1894 [1437–2424]	1870.5 [1436.8–2427.8]	2383 [1354–2656]	0.44
Postoperative CME at 1 M, n (%)	15 (7.3)	15 (9.4)	0 (0)	*0.02*
Postoperative BCVA at 3 M, median [IQR], logMAR	0 (−0.08 to 0.22)	0.046 (−0.08 to 0.30)	0 (−0.08 to 0.05)	*0.004*
Postoperative anterior inflammation at 3 M, median [IQR], flare grade	15.3 (10.5–21.6) (n = 57)	15.3 (10.5–21.6) (n = 57)	N.A.
Postoperative number of corneal endothelial cells at 3 M, median [IQR]	1715 [1410–2420]	1714 [1423–2418]	2456 [1831–2908]	0.13
Postoperative CME at 3 M, n (%)	22 (10.6)	21 (13.0)	1 (1.9)	*0.02*
Absence of postoperative transient ocular hypotension, n (%)	37 (18.1)	30 (19.0)	9 (17.3)	0.79
Absence of postoperative IOL capture, n (%)	7 (3.4)	6 (3.8)	1 (1.9)	1.0
Absence of postoperative VH, n (%)	5 (2.4)	5 (3.1)	1 (1.9)	1.0
Duration of postoperative steroid drop use, median [IQR], weeks	4 [4–10]	5 [4–12]	4 [4–4]	*0.007*
Duration of postoperative NSAID ⁱ drop use, median [IQR], weeks	12 [4–12]	8 [4–12]	12 [12–12]	*0.005*

BCVA, best−corrected visual acuity; CME, cystoid macular oedema; IOL, intraocular lens; IQR, interquartile range; logMAR, logarithm of the minimum angle of resolution; NSAID, non−steroidal anti−inflammatory drug; VH, vitreous haemorrhage; 1 M, 1 month; 3 M, 3 months.
Bold italics indicate statistical significance (p < 0.05).

Quick links

Search